The AHA today urged the Centers for Medicare & Medicaid Services to consider alternative payment solutions to promote beneficiary access to chimeric antigen receptor T-cell (CAR T) therapy and other new technologies that “offer extraordinary potential to save lives, but are also associated with extraordinary costs.” In a letter to CMS, AHA recommended immediate and longer-term actions to “promote beneficiary access to these therapies, set appropriate precedents for how they are handled in rating setting and preserve opportunities for additional payment options in the future.” On Friday, CMS proposed that Medicare cover CAR T therapies approved by the Food and Drug Administration when they are prescribed by the treating oncologist and performed in a hospital meeting certain criteria.

Related News Articles

Headline
The AHA Aug. 28 expressed support for the Preserving Patient Access to Accountable Care Act in comments to House and Senate sponsors of the bill. The…
Headline
The AHA’s Society for Health Care Strategy & Market Development Aug. 21 announced Donna Teach, chief marketing and communications officer for Nationwide…
Headline
The Department of Health and Human Services and the Centers for Medicare & Medicaid Services Aug. 21 announced the creation of a Healthcare Advisory…
Headline
A JAMA study published Aug. 18 found that plan design changes by Medicare Part D insurers, particularly for Medicare Advantage plans, following passage of the…
Perspective
Public
The job description for the ideal health care leader in coming years might read something like this:Wanted: Bold, compassionate innovator who unites clinical…
Headline
The AHA’s Next Generation Leaders Fellowship July 29 announced its 36 fellows for the class of 2026, who will each work with mentors to address a specific…